Enzalutamide and PSA: What Prostate Cancer Patients Should Know

 

A prostate-specific antigen (PSA) test is one of the important tools doctors use to monitor prostate cancer. For people taking enzalutamide, changes in PSA can provide useful information about how the disease is responding to treatment.

But PSA is not the whole story.

A lower PSA can be encouraging, while a rising PSA may warrant further evaluation. However, PSA results need to be interpreted alongside other information, including symptoms, testosterone levels, imaging findings, previous treatment, and the stage of prostate cancer.

Here is what the relationship between enzalutamide and PSA really means.

What is PSA?

Prostate-specific antigen, or PSA, is a protein produced by prostate cells. A blood test measures the amount of PSA in the bloodstream.

PSA can be used in different ways depending on a person’s situation. It may help with prostate cancer detection and risk assessment, and it is also commonly used to monitor men who have already been diagnosed with prostate cancer.

The meaning of a PSA result depends on the clinical context. A single PSA number does not by itself diagnose prostate cancer or determine whether treatment is working. The European Association of Urology notes that PSA assessment and its interpretation depend on the patient’s circumstances and that changes in PSA should be considered alongside other clinical information.

How does enzalutamide affect PSA?

Enzalutamide is an androgen receptor inhibitor used in the treatment of certain types and stages of prostate cancer. It works by interfering with androgen-receptor signalling, which can reduce the ability of prostate cancer cells to use androgen signals for growth.

Press enter or click to view image in full size

Because PSA production is androgen-dependent, effective androgen-receptor inhibition can be associated with a reduction in serum PSA. The National Cancer Institute describes this relationship as one of the effects associated with enzalutamide’s activity against prostate cancer cells.

This is why doctors may monitor PSA while a patient is receiving enzalutamide.

However, a PSA response should not be interpreted in isolation.

What does a PSA decline after starting enzalutamide mean?

A decline in PSA can indicate that the cancer is responding to treatment, particularly when the change occurs together with a favourable clinical picture.

Press enter or click to view image in full size

Clinical studies have reported substantial PSA responses in some men receiving enzalutamide. For example, research in patients with metastatic castration-resistant prostate cancer reported confirmed PSA declines of at least 50% in a proportion of patients treated with enzalutamide.

But patients respond differently.

The amount and timing of PSA change can vary depending on factors such as:

• The stage and biology of the prostate cancer
• Previous treatments
• Whether the cancer is castration-sensitive or castration-resistant
• Testosterone levels
• The presence or absence of metastatic disease
• Other treatments being given at the same time

Therefore, there is no single PSA number that can be used to predict the outcome for every person taking enzalutamide.

Can enzalutamide lower PSA levels?

Yes. Enzalutamide can be associated with lower PSA levels because it blocks androgen-receptor signalling involved in prostate cancer growth and PSA production.

But it is important to understand what this does not mean.

A falling PSA does not automatically prove that every cancer cell has disappeared. Similarly, the PSA response does not necessarily provide a complete picture of what is happening in metastatic disease.

The European Association of Urology’s current guidance highlights an important point: during androgen deprivation therapy combined with an androgen-receptor pathway inhibitor, relying on PSA alone can miss some cases of radiographic progression. In the PREVAIL study, for example, some men receiving enzalutamide experienced radiographic progression without an accompanying PSA increase.

That is why doctors may combine PSA testing with imaging, symptoms, physical assessment, and other laboratory measurements.

What does a rising PSA mean while taking enzalutamide?

A rising PSA during treatment does not automatically mean that enzalutamide has stopped working.

It can be a reason for the treating team to investigate further.

Doctors may consider:

• The pattern and speed of the PSA increase
• The patient’s symptoms
• Testosterone levels
• Imaging results
• The duration of treatment
• Previous and current cancer treatments
• Whether the patient is taking the medicine as prescribed

The EAU recommends checking testosterone when progression is suspected because confirming a castration-resistant state requires testosterone to remain at a castrate level. The guideline also recommends restaging when disease progression is suspected.

This is particularly important because prostate cancer can sometimes progress without a corresponding PSA rise.

Why PSA alone cannot tell the whole story

It is tempting to think of PSA as a simple score:

PSA down = treatment working
PSA up = treatment failing

Real-world prostate cancer monitoring is more complicated.

The current EAU guidance specifically warns that stable PSA does not always mean that metastatic prostate cancer is not progressing. Regular imaging may still be needed, even when PSA remains stable, depending on the patient’s disease and treatment.

For someone receiving enzalutamide, the treating physician may therefore look at several pieces of information together.

PSA

Shows how the prostate-specific antigen level is changing over time.

Testosterone

Helps determine whether adequate androgen suppression has been achieved and maintained, particularly when castration-resistant prostate cancer is being assessed.

Imaging

CT, MRI, bone imaging, or other appropriate imaging may help identify changes that PSA alone cannot reveal.

Symptoms

New or worsening symptoms can provide important information about disease activity and treatment response.

Overall clinical assessment

The patient’s medical history, previous therapies, disease stage, laboratory results, imaging and symptoms all contribute to treatment decisions.

What is PSA progression?

The term PSA progression generally refers to a clinically meaningful increase in PSA according to criteria appropriate to the patient’s disease setting and treatment.

It should not be confused with simply having one higher PSA test result.

PSA can fluctuate, and the significance of a change depends on the patient’s previous PSA values, treatment history and clinical circumstances.

For this reason, patients should avoid interpreting an isolated PSA result without discussing it with their oncology or urology team.

Enzalutamide, PSA and castration-resistant prostate cancer

Enzalutamide has an important role in the treatment of several prostate cancer settings, including castration-resistant disease and certain hormone-sensitive disease settings. The NCI lists approved uses that include castration-resistant prostate cancer as well as specific castration-sensitive prostate cancer settings.

In castration-resistant prostate cancer, PSA monitoring is particularly relevant because PSA can provide information about disease activity during systemic treatment.

However, a diagnosis of castration-resistant prostate cancer is not based on PSA alone. Testosterone levels and evidence of biochemical, radiographic or clinical progression are important components of the assessment.

How often should PSA be checked while taking enzalutamide?

There is no single testing schedule that applies to every person.

The appropriate monitoring interval depends on factors such as:

• Cancer stage
• Treatment regimen
• Previous treatments
• Symptoms
• PSA pattern
• Testosterone levels
• Whether metastatic disease is present

Current EAU guidance recommends individualized follow-up. For men with metastatic disease receiving hormonal treatment, follow-up generally includes regular clinical assessment and imaging, with the schedule adapted to the individual situation.

Your treating doctor should determine when PSA and other tests are appropriate.

What should patients ask their doctor about PSA while taking enzalutamide?

If you are receiving enzalutamide, useful questions may include:

1. What was my PSA before starting treatment?
2. What trend are you looking for in my PSA?
3. How often should my PSA be checked?
4. Should my testosterone level also be monitored?
5. Do I need imaging even if my PSA is falling?
6. What would a sustained PSA increase mean in my situation?
7. Could other factors affect my PSA result?
8. How will PSA, symptoms and imaging be considered together?

These questions can help patients understand their treatment monitoring without trying to interpret individual results on their own.

The bottom line

Enzalutamide and PSA are closely connected in prostate cancer monitoring, but PSA should never be viewed as the only measure of treatment response.

Enzalutamide can reduce androgen-receptor signalling and may lead to a decline in PSA in responding patients. At the same time, prostate cancer can sometimes progress without a significant PSA increase, making clinical assessment and imaging important parts of follow-up.

If your PSA changes while you are taking enzalutamide, discuss the result with your treating physician rather than changing or stopping treatment based on the number alone.

Patients, caregivers or wholesale buyers looking for Enzalutamide or other speciality medicines can contact Letsmeds to ask about product availability, strength, pricing, and ordering requirements. LetsMeds provides Enzalutamide and other medicines. Patients should use Enzalutamide only as prescribed by their healthcare professional.

Medical Disclaimer

This article is intended for general educational purposes and does not replace advice from a qualified oncologist, urologist or other healthcare professional. Enzalutamide is a prescription medicine, and treatment decisions should be based on an individual’s diagnosis, disease stage, treatment history and medical condition.

Suggested sources for readers: National Cancer Institute (NCI) and European Association of Urology (EAU) prostate cancer guidance. The EAU’s 2026 update also highlights ongoing changes in prostate cancer treatment and the evolving role of enzalutamide in specific disease settings.